

EQA round: APLA1/23 - Antiphospholipid Antibodies

Deadline: 17.3.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]	
(465) anti-β2-glycoprotein 1 screening		13			13	13	100	
Sample A		13			13	13	100	
(2) EIA (ELISA)	CVP >>>	12	92	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	7,7	Positive				
Sample B		13			13	13	100	
(2) EIA (ELISA)	CVP >>>	12	92	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	7,7	Positive				
(467) anti-β2-glycoprotein 1 IgG		61			61	61	100	
Sample A		61			61	61	100	
(0) Not specified	CVP >>>	1	1,6	Positive				
(2) EIA (ELISA)	CVP >>>	38	62	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	3	4,9	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	31	Positive				
Sample B		61			61	61	100	
(0) Not specified	CVP >>>	1	1,6	Positive				
(2) EIA (ELISA)	CVP >>>	38	62	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	3	4,9	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	31	Positive				
(468) anti-β2-glycoprotein 1 IgM		60			60	59	98	
Sample A		60			0			
(0) Not specified	±	1	1,7	Negative				
(2) EIA (ELISA)	±	23	38	Negative				
	±	6	10	Inconclusive result (borderline)				
	±	8	13	Positive				
(3) FIA (FEIA, TRACE)	±	3	5	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	±	18	30	Negative				
(99) Another measurement principle	±	1	1,7	Negative				
Sample B		60			60	59	98	
(0) Not specified	CVP >>>	1	1,7	Negative				
(2) EIA (ELISA)	CVP >>>	36	60	Negative				
		1	1,7	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	3	5	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	18	30	Negative				
(99) Another measurement principle	CVP >>>	1	1,7	Negative				
(461) anti-cardiolipin screening		16			16	16	100	
Sample A		16			16	16	100	
(2) EIA (ELISA)	CVP >>>	15	94	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	6,3	Positive				
Sample B		16			16	16	100	
(2) EIA (ELISA)	CVP >>>	15	94	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	1	6,3	Positive				
(463) anti-cardiolipin IgG		65			65	65	100	
Sample A		65			0			
(2) EIA (ELISA)	±	8	12	Negative				
	±	1	1,5	Inconclusive result (borderline)				
	±	31	48	Positive				
(3) FIA (FEIA, TRACE)	±	4	6,2	Negative				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	±	20	31	Positive				
(99) Another measurement principle	±	1	1,5	Positive				
Sample B		65			65	65	100	
(2) EIA (ELISA)	CVP >>>	40	62	Positive				
(3) FIA (FEIA, TRACE)	CVP >>>	4	6,2	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	20	31	Positive				
(99) Another measurement principle	CVP >>>	1	1,5	Positive				
(464) anti-cardiolipin IgM		64			64	59	92	
Sample A		64			64	59	92	
(2) EIA (ELISA)	CVP >>>	30	47	Negative				
	>	6	9,4	Inconclusive result (borderline)				
		4	6,3	Positive				
(3) FIA (FEIA, TRACE)	>	3	4,7	Inconclusive result (borderline)				
		1	1,6	Positive				
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	19	30	Negative				
	>	1	1,6	Inconclusive result (borderline)				

EQA round: APLA1/23 - Antiphospholipid Antibodies

Deadline: 17.3.2023

Setup: groups - measurement principle

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
Sample B		64					
(2) EIA (ELISA)	CVP >>>	40	63	Negative	64	64	100
(3) FIA (FEIA, TRACE)	CVP >>>	4	6.3	Negative			
(4) LIA (CLIA, CMIA, ECLIA, LOCI)	CVP >>>	20	31	Negative			